AMGN FDA Monday, September 14, 2026 0.00 Neutral

Amgen Says FDA Approved Prescribing Information Update Cutting IMDELLTRA Monitoring Time For First Two Doses To 6 To 8 Hours From 22 To 24 Hours

Amgen Says FDA Approved Prescribing Information Update Cutting IMDELLTRA Monitoring Time For First Two Doses To 6 To 8 Hours From 22 To 24 Hours

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day